Business Wire

ADTRAN

16.7.2024 14:01:35 CEST | Business Wire | Press release

Share
telMAX uses Adtran Mosaic CP with GLDS BroadHub® to streamline network expansion

Adtran today announced that telMAX is leveraging its scalable, programmable fiber access technology as it extends its high-speed broadband services to many more communities. The Canadian service provider is harnessing Adtran’s Mosaic CP microservices platform integrated with GLDS BroadHub® subscriber management platform to enable rapid, cost-effective expansion of its network. With advanced automation features, the technology streamlines network management and service activation, empowering telMAX to enhance service delivery, troubleshooting and customer care. The new solution is built on Adtran’s compact SDX 6000 Series of Combo PON optical line terminals (OLTs), along with Adtran’s multigigabit XGS-PON optical network terminals, designed for the most bandwidth-intensive subscribers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716856855/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adtran’s fiber access technology is helping telMAX rapidly expand into new areas. (Photo: Business Wire)

“At telMAX, our mission is to be the premier telecommunications provider in Canada, offering the fastest internet services and the best customer care experience. Leveraging Adtran’s technology has been instrumental in this goal. It’s enabled us to deliver exceptional speed and service, helping us earn recognition from PCMag as Canada’s Fastest ISP for the last two years running,” said Stuart Robert, president of telMAX. “Our new fiber access solution empowers us to perform many operations remotely, ensuring swift, trouble-free installations for our subscribers. The capability to quickly deploy and activate equipment optimizes productivity and significantly reduces manual efforts and operational costs. This efficiency enables us to rapidly expand into new areas, creating ‘fiberhoods’ where residents can enjoy exclusive, lightning-fast internet connectivity.”

telMAX is extending its network to reach more communities across the Greater Toronto Area. Today, they serve a growing customer base in the areas of Newmarket, Stouffville, Brooklin and Aurora. Leveraging Adtran’s technology, including the Mosaic CP platform and SDX Series of OLTs integrated with the GLDS BroadHub® subscriber management and service delivery platform, telMAX is well-equipped to meet the demands of these new markets. The integration allows for real-time adjustments to network conditions and rapid responses to customer demands, significantly enhancing operational efficiencies and scalability. It eliminates swivel-chair operations, removing operational barriers that can slow down workflows, complicate fiber rollouts and introduce friction into customer interactions. By enhancing service quality, minimizing downtime and ensuring heightened network reliability, telMAX will be able to provide superior connectivity and support to its expanding customer base.

“This deployment gives telMAX a more agile and customer-focused network, significantly increasing overall satisfaction as they bring ultra-fast full-fiber broadband to more households and businesses in Southern Ontario,” commented John Scherzinger, GM of Americas sales at Adtran. “Our technology is powering telMAX’s rapid growth, enabling them to expand their network while fostering community development. Seamless connectivity, reaching every street and neighborhood, will bridge the connectivity gap and enhance community engagement. Today’s digitally driven world demands intelligent, flexible networks that guarantee superior service quality. By adopting our Mosaic CP and GLDS’s BroadHub®, telMAX is at the forefront of efforts to transform networks to be more responsive to evolving subscriber needs and expectations.”

“Pairing the subscriber-centered functionality of our BroadHub® platform with the control and orchestration capabilities of Adtran’s Mosaic CP enables telMAX to streamline service delivery and elevate the customer experience. BroadHub® is designed to provide comprehensive customer management and billing solutions that manage the complete customer lifecycle. This integration allows telMAX to simplify operations and efficiently deliver superior customer care,” noted Adam Ross Hill, partner alliance manager at GLDS. “Today’s broadband subscribers expect interactions with their service provider to be efficient and accurate. Using our platform, telMAX can automate service delivery and save their technicians and customers valuable time. In addition to boosting subscriber satisfaction, BroadHub® also offers a cost-effective way to enhance operational efficiency, supporting telMAX’s growth and commitment to community empowerment.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716856855/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye